DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis

Acta Tropica

Volumn 120, Issue 3, 2011, Pages 185-190

  da Silva, Robson A A ^a,b,c   Tavares, Natália M ^a   Costa, Dirceu ^a   Pitombo, Maiana ^a   Barbosa, Larissa ^a   Fukutani, Kyioshi ^a   Miranda, Jose C ^a   de Oliveira, Camila I ^a   Valenzuela, Jesus G ^f   Barral, Aldina ^a   Soto, Manuel ^e   Barral Netto, Manoel ^a   Brodskyn, Cláudia ^d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Instituto de Ciências da Saúde e Faculdade de Medicina   (Brazil)

^d Instituto Nacional de Ciencia e Tecnologia de Investigacao em Imunologia III INCT   (Brazil)

^e CSIC   (Spain)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

DNA plasmids; Hamster; Leishmania chagasi; Protection; Saliva; Visceral leishmaniasis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; PLASMID DNA; SALIVA PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

DNA; HEMATOLOGY; IMMUNIZATION; PROTEIN; RODENT; VACCINATION;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG EFFECT; LEISHMANIA CHAGASI; LIVER; LUTZOMYIA; LUTZOMYIA LONGIPALPIS; MALE; NONHUMAN; PARASITE LOAD; PROTECTION; SPLEEN; SYRIAN HAMSTER; VISCERAL LEISHMANIASIS;

ANIMALS; CRICETINAE; FEMALE; INSECT PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIASIS, VISCERAL; LIVER; LYMPH NODES; MALE; MEMBRANE GLYCOPROTEINS; MESOCRICETUS; PROTOZOAN PROTEINS; PSYCHODIDAE; RECOMBINANT PROTEINS; SALIVARY PROTEINS AND PEPTIDES; SPLEEN; TRANSFORMING GROWTH FACTOR BETA; VACCINES, DNA;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI; LEISHMANIA DONOVANI CHAGASI; LUTZOMYIA LONGIPALPIS; PHLEBOTOMINAE;

EID: 80054868399     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.08.007     Document Type: Article

References (34)

1. Andrade B.B., de Oliveira C.I., Brodskyn C.I., Barral A., Barral-Netto M. Role of sand fly saliva in human and experimental leishmaniasis: current insights. Scand. J. Immunol. 2007, 66:122-127.
2. Barral A., Honda E., Caldas A., Costa J., Vinhas V., Rowton E.D., Valenzuela J.G., Charlab R., Barral-Netto M., Ribeiro J.M. Human immune response to sand fly salivary gland antigens: a useful epidemiological marker?. Am. J. Trop. Med. Hyg. 2000, 62:740-745.
3. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005, 174:7160-7171.
4. Basu R., Roy S., Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 2007, 195:1373-1380.
5. Belkaid Y., Kamhawi S., Modi G., Valenzuela J., Noben-Trauth N., Rowton E., Ribeiro J., Sacks D.L. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 1998, 188:1941-1953.
6. Caldas A.J., Costa J., Aquino D., Silva A.A., Barral-Netto M., Barral A. Are there differences in clinical and laboratory parameters between children and adults with American visceral leishmaniasis?. Acta Trop. 2006, 97:252-258.
7. Costa D.J., Favali C., Clarencio J., Afonso L., Conceicao V., Miranda J.C., Titus R.G., Valenzuela J., Barral-Netto M., Barral A., Brodskyn C.I. Lutzomyia longipalpis salivary gland homogenate impairs cytokine production and costimulatory molecule expression on human monocytes and dendritic cells. Infect. Immun. 2004, 72:1298-1305.
8. Dondji B., Perez-Jimenez E., Goldsmith-Pestana K., Esteban M., McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect. Immun. 2005, 73:5286-5289.
9. Fernandez-Guerrero M.L., Robles P., Rivas P., Mojer F., Muniz G., de Gorgolas M. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop. 2004, 90:11-16.
10. Fuertes M.A., Perez J.M., Soto M., Lopez M.C., Alonso C. Calcium-induced conformational changes in Leishmania infantum kinetoplastid membrane protein-11. J. Biol. Inorg. Chem. 2001, 6:107-117.
11. Gantt K.R., Schultz-Cherry S., Rodriguez N., Jeronimo S.M., Nascimento E.T., Goldman T.L., Recker T.J., Miller M.A., Wilson M.E. Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 2003, 170:2613-2620.
12. Gomes R., Teixeira C., Teixeira M.J., Oliveira F., Menezes M.J., Silva C., de Oliveira C.I., Miranda J.C., Elnaiem D.E., Kamhawi S., Valenzuela J.G., Brodskyn C.I. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7845-7850.
13. Greenland J.R., Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007, 25:3731-3741.
14. Guilpin V.O., Swardson-Olver C., Nosbisch L., Titus R.G. Maxadilan, the vasodilator/immunomodulator from Lutzomyia longipalpis sand fly saliva, stimulates haematopoiesis in mice. Parasite Immunol. 2002, 24:437-446.
15. Kamhawi S., Belkaid Y., Modi G., Rowton E., Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000, 290:1351-1354.
16. Lima H.C., Titus R.G. Effects of sand fly vector saliva on development of cutaneous lesions and the immune response to Leishmania braziliensis in BALB/c mice. Infect. Immun. 1996, 64:5442-5445.
17. Lima H.C., Bleyenberg J.A., Titus R.G. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol. Today 1997, 13:80-82.
18. Melby P.C., Tryon V.V., Chandrasekar B., Freeman G.L. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokines mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 1998, 66:2135-2142.
19. Melby P.C., Chandrasekar B., Zhao W., Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 2001, 166:1912-1920.
20. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., Carrillo E., Napp S., Reymond C., Kaye P.M., Smith D.F., Fasel N., Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 2007, 25:5290-5300.
21. Morris R.V., Shoemaker C.B., David J.R., Lanzaro G.C., Titus R.G. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol. 2001, 167:5226-5230.
22. Nylen S., Maurya R., Eidsmo L., Manandhar K.D., Sundar S., Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 2007, 204:805-817.
23. Oliveira F., Kamhawi S., Seitz A.E., Pham V.M., Guigal P.M., Fischer L., Ward J., Valenzuela J.G. From transcriptome to immunome: identification of DTH inducing proteins from a Phlebotomus ariasi salivary gland cDNA library. Vaccine 2006, 24:374-390.
24. Olivier M., Gregory D.J., Forget G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin. Microbiol. Rev. 2005, 18:293-305.
25. Pastorino A.C., Jacob C.M., Oselka G.W., Carneiro-Sampaio M.M. Visceral leishmaniasis: clinical and laboratorial aspects. J. Pediatr. (Rio J) 2002, 78:120-127.
26. Ramirez J.R., Gilchrist K., Robledo S., Sepulveda J.C., Moll H., Soldati D., Berberich C. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine 2001, 20:455-461.
27. Ribeiro J.M. Blood-feeding arthropods: live syringes or invertebrate pharmacologists?. Infect. Agents Dis. 1995, 4:143-152.
28. Ribeiro J.M., Modi G. The salivary adenosine/AMP content of Phlebotomus argentipes Annandale and Brunetti, the main vector of human kala-azar. J. Parasitol. 2001, 87:915-917.
29. Sharma G., Anabousi S., Ehrhardt C., Ravi Kumar M.N. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J. Drug Target. 2006, 14:301-310.
30. Silva F., Gomes R., Prates D., Miranda J.C., Andrade B., Barral-Netto M., Barral A. Inflammatory cell infiltration and high antibody production in BALB/c mice caused by natural exposure to Lutzomyia longipalpis bites. Am. J. Trop. Med. Hyg. 2005, 72:94-98.
31. Theodos C.M., Ribeiro J.M., Titus R.G. Analysis of enhancing effect of sand fly saliva on Leishmania infection in mice. Infect. Immun. 1991, 59:1592-1598.
32. Titus R.G., Ribeiro J.M. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988, 239:1306-1308.
33. Valenzuela J.G., Belkaid Y., Garfield M.K., Mendez S., Kamhawi S., Rowton E.D., Sacks D.L., Ribeiro J.M. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med. 2001, 194:331-342.
34. Yarali N., Fisgin T., Duru F., Kara A. Myelodysplastic features in visceral leishmaniasis. Am. J. Hematol. 2002, 71:191-195.